JCO Global Oncology (Dec 2021)

Trends in International Cancer Research Investment 2006-2018

  • Rachel Abudu,
  • Gauthier Bouche,
  • Karima Bourougaa,
  • Lynne Davies,
  • Kalina Duncan,
  • Carla Estaquio,
  • Anna Diaz Font,
  • Marc S. Hurlbert,
  • Paul Jackson,
  • Linda Kroeskop-Bossenbroek,
  • Ian Lewis,
  • Giota Mitrou,
  • Abdul Mutabbir,
  • Christopher A. Pettigrew,
  • Lynn Turner,
  • Annemarie Weerman,
  • Kari Wojtanik

DOI
https://doi.org/10.1200/GO.20.00591
Journal volume & issue
no. 7
pp. 602 – 610

Abstract

Read online

The International Cancer Research Partnership (ICRP) is an active network of cancer research funding organizations, sharing information about funded research projects in a common database. Data are publicly available to enable the cancer research community to find potential collaborators and avoid duplication. This study presents an aggregated analysis of projects funded by 120 partner organizations and institutes in 2006-2018, to highlight trends in cancer research funding. Overall, the partners’ funding for cancer research increased from $5.562 billion (bn) US dollars (USD) in 2006 to $8.511bn USD in 2018, an above-inflation increase in funding. Analysis by the main research focus of projects using Common Scientific Outline categories showed that Treatment was the largest investment category in 2018, followed by Early Detection, Diagnosis, and Prognosis; Cancer Biology; Etiology; Control, Survivorship, and Outcomes; and Prevention. Over the 13 years covered by this analysis, research funding into Treatment and Early Detection, Diagnosis, and Prognosis had increased in terms of absolute investment and as a proportion of the portfolio. Research funding in Cancer Biology and Etiology declined as a percentage of the portfolio, and funding for Prevention and Control, Survivorship and Outcomes remained static. In terms of cancer site–specific research, funding for breast cancer and colorectal cancer had increased in absolute terms but declined as a percentage of the portfolio. By contrast, investment for brain cancer, lung cancer, leukemia, melanoma, and pancreatic cancer increased both in absolute terms and as a percentage of the portfolio.